Abstract:Background: TNM stage alone cannot accurately predict the recurrence risk after curative resection of colorectal cancer (CRC) and the benefit of adjuvant chemotherapy for patients with stage II CRC. We assessed the value of prothrombin time (PT) and carcinoembryonic antigen (CEA) levels in recurrence prediction and whether the combination of PT and CEA levels and TNM stage can improve the accuracy in predicting postoperative recurrence of CRC.Methods: The coagulation indexes and tumor markers of 451 patients with CRC were analyzed retrospectively. Log-rank test, Cox proportional hazard regression model and Kaplan-Meier survival curve were used to analyze the value of these indexes in predicting postoperative recurrence in different TNM stage subgroups.Results: Preoperatively elevated levels of PT (≥12.65s) and CEA (≥ 10.175ng/ml) were independent factors affecting postoperative recurrence of CRC (p < 0.05 and p < 0.01, respectively). 451 CRC patients were divided into three groups according to preoperative levels of PT and CEA. The 5-year cumulative recurrence rate (CRR) and recurrence-free survival (RFS) differed significantly among the High-risk (PT ≥12.65s and CEA≥ 10.175ng/ml), Middle-risk (PT ≥12.65s or CEA≥ 10.175ng/ml), and Low-risk (PT < 12.65s and CEA < 10.175ng/ml) groups (p < 0.001). Patients in the High-risk group even have a significantly higher 5-year CRR and shorter RFS than those in TNM stage III (5-year CRR: 67.2% vs 48.7%, p < 0.001; RFS: 33.7 months vs 39.7 months, p < 0.001). PT and CEA as biomarkers for prognostic stratification showed that, in the subgroup of stage III, the 5-year CRR of the High-risk group was more than twice that of the Low-risk group (71.1% vs 31.8%, p < 0.001), and the RFS was 16.1 months shorter than that of the Low-risk group (30.1 vs 46.2, p < 0.001). In the subgroup of early-stage (stage I and II), the 5-year CRR in the High-risk group was more than 3 times higher than that in the Low-risk group (61.5%vs 18.4%; p < 0.001), and even higher than that in stage IIIA and B (61.5% vs 36.4%; p < 0.001) and similar to that in stage IIIC (61.5% vs 62.9%; p >0.05); moreover, the RFS of the High-risk group of early-stage was notably shorter than that of the Low-risk group (38.9 vs 53 months; p < 0.001) and even that of IIIA and B (38.9 vs 45.2 months; p < 0.05).Conclusion: Preoperatively elevated levels of PT and CEA were reliable predictors of postoperative high recurrence in CRC patients. Incorporation of PT and CEA levels to a recurrence prediction model with TNM stage can precisely identify a subgroup of CRC patients with -risk of recurrence in stage I-III, especially the risk of recurrence population in stage I and II.Funding Information: This work was supported by the National Natural Science Foundation of China (81502039), the Natural Science Foundation of Fujian Province (2016J01616 and 2020J011214), the Health and Family Planning Commission of Fujian Province for Youth Research Project (2015-2-49), the Scientific Research Foundation for Returned Scholars from Ministry of Human Resources and Social Security (2015142), and the Digestive Center of Xiamen University Foundation.Declaration of Interests: The authors had declared no conflict of interest.Ethics Approval Statement: This study was approved by the Ethics Review Committee of Zhongshan Hospital of Xiamen University and the informed consent of the patients was obtained.

Preoperative Serum Carcinoembryonic Antigen, Carbohydrate Antigen19-9 and Carbohydrate Antigen 125 as Prognostic Factors for Recurrence-free Survival in Colorectal Cancer

Preoperative Serum Carbohydrate Antigen 125 Level is an Independent Negative Prognostic Marker for Overall Survival in Colorectal Cancer

Combined Detection of Preoperative Serum CEA, CA19-9 and CA242 Improve Prognostic Prediction of Surgically Treated Colorectal Cancer Patients.

Preoperative CA19-9: a Competitive Predictor of Recurrence in Patients with Colorectal Cancer Liver Metastases after Hepatectomy

The Prognostic Value of Preoperative Serum CEA and CA19-9 Values in Stage I ~ III Colorectal Cancer

The prognostic value of preoperative serum CA724 for CEA-normal colorectal cancer patients

Prognostic Value Of Pretreatment Serum Carbohydrate Antigen 19-9 Level In Patients With Colorectal Cancer: A Meta-Analysis

Combined Evaluation of Preoperative Serum CEA and CA125 As an Independent Prognostic Biomarker in Patients with Early-Stage Cervical Adenocarcinoma

Trajectories of Perioperative Serum Tumor Markers and Colorectal Cancer Outcomes: A Retrospective, Multicenter Longitudinal Cohort Study

Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study

Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases

Predictive value of preoperative and postoperative serum tumor markers CEA, CA19 9, and CA72 4 in the diagnosis of gastric cancer recurrence at different stages

[Predictive Value of Preoperative Detection of CEA and CA199 for Prognosis in Patients with Stage II-III Colorectal Cancer].

High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy

Preoperative Serum Carbohydrate Antigen 242 is a Useful Predictive and Prognostic Marker in Colorectal Cancer.

Prognostic Value of Preoperative Serum Tumor Markers in Gastric Cancer

Combining PT and CEA Levels with the TNM Stage System to Identify Postoperative Recurrence Patients with Stage I-III Colorectal Cancer

Identifying tumor markers-stratified subtypes (CA-125/CA19-9/carcinoembryonic antigen) in cervical adenocarcinoma

Prognostic Significance of Preoperative and Postoperative Evaluation of Combined Tumor Markers for Patients With Colon Cancer

Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer